Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups working on solutions for the pharma sector. As there is a large number of startups working on a wide variety of solutions, we decided to share our insights with you. This time, we are taking a look at 5 promising monoclonal antibody solutions.
Heat Map: 5 Top Monoclonal Antibody Solutions
Using our StartUs Insights Platform, covering 1.116.000+ startups & emerging companies, we looked at innovation in the field of pharma. For this research, we identified 128 relevant solutions and picked 5 to showcase below. These companies are chosen based on a data-driven startup scouting approach, taking into account factors such as location, founding year, and relevance of technology, among others. Depending on your specific criteria, the top picks might look entirely different.
The Global Startup Heat Map below highlights 5 startups & emerging companies developing innovative monoclonal antibody solutions. Moreover, the Heat Map reveals regions that observe a high startup activity and illustrates the geographic distribution of all 128 companies we analyzed for this specific topic.
Click to download
Aridis Pharmaceuticals – Human Monoclonal Antibody (mAb)
Antibiotic resistance is a pandemic affecting almost all the countries in the world. The widespread unregulated use of antibiotics, along with the rapid mutation rates of infectious microbes, makes it difficult to tackle antibiotic resistance. The specificity offered by antibacterial monoclonal antibodies (mAb), as compared to the existing antibiotics, makes mAbs a promising treatment to deal with antibiotic resistance.
The US-based startup Aridis Pharmaceuticals develops monoclonal antibody discovery platforms for tackling antibiotic-resistant infections. These platforms find and recover B-cells from individuals who have survived antibiotic-resistant infections. Their development pipeline includes drugs targeting staphylococcus aureus, pseudomonas aeruginosa, as well as Acinetobacter baumannii infections.
Igyxos – Infertility Treatment
Hormonal imbalances are the major reason for infertility, a condition that affects a significant number of couples around the world. The levels of gonadotropins, the hormones involved in the regulation of the reproductive cycle, are altered in these patients. Hormone replacement therapies are a popular treatment option for infertility, but have low success rates and are often highly expensive.
French startup Igyxos is developing a monoclonal antibody-based treatment for female and male infertility. The startup designs the antibody to potentiate the bioactivity of endogenous and exogenous gonadotropins. In addition, the solution induces ovulation in women and regulates spermatogenesis in men by bio-activating gonadotrophins.
Solvanix – Antibody Stability
Many monoclonal antibody drugs in development have suboptimal colloidal stability and tend to aggregate, mainly due to changes in acidity (pH), ionic strength, different buffers, and additive types. This negatively impacts the drug development process and incurs huge losses for pharma companies. Antibody stability is crucial for cost-effective manufacturing, increasing shelf-life, cold-chain logistics, and overall drug efficacy.
Australia based startup Solvanix develops StAbilize, a technology for stabilizing antibodies. The startup’s solution optimizes the amino acids within the antibody’s complementarity determining regions (CDRs). This improves colloidal stability and minimizes the aggregation of monoclonal antibody products. The technology serves a variety of antibody formats, including fragments, bi-specifics, and full-length immunoglobin G (IgG) monoclonals. Antibodies incorporated with StAbilize also have lower adverse immune reactions.
Yurogen Biosystems – Humanized mAb
Monoclonal antibodies have multiple methods of production and are named based on their origin. Murines are derived from mice whereas chimeric contain parts from different species. Humanized monoclonal antibodies contain small non-human portions, as compared to chimeric mAbs. In general, lower levels of anti-drug antibodies are produced in response to humanized mAb introduction into the body.
The US-based startup Yurogen Biosystems is developing humanized mAbs. The startup’s single-cell based monoclonal antibody (SMab) platform produces mAbs from different host species such as rabbits, monkeys, and humans. The startup offers antibody humanization services for many different kinds of mAbs.
Tychan – Rapid Development
The successful development and launch of novel drug candidates, especially biologics, take anywhere between 10 to 15 years. The spread of several new viral diseases such as Zika and the novel coronavirus (SARS-CoV-2) poses a great threat and calls for rapid drug discovery and development processes. Startups are working on new ways to tackle this challenge and introducing effective drugs fast.
Singapore based Tychan is a clinical-stage startup that develops a technology platform. The startup uses convergent analytics to enable the rapid development of biologics for human trials. The solution offers two monoclonal antibody therapeutics – Tyzivumab, for the Zika virus, and TY014, for yellow fever virus. Tychan’s platform significantly reduces the time taken to bring these therapeutics from candidates to the Investigational New Drug (IND) filing stage. TY027, a monoclonal antibody for neutralizing SARS-CoV-2, is currently undergoing preclinical trials.
What About The Other 123 Solutions?
While we believe data is key to creating insights it can be easy to be overwhelmed by it. Our ambition is to create a comprehensive overview and provide actionable innovation intelligence that enables you to achieve your goals faster. The 5 monoclonal antibody solutions showcased above are promising examples out of 128 we analyzed for this article. To identify the most relevant solutions based on your specific criteria, get in touch.
